In a world of constant connectivity and mounting pressures, generalized anxiety disorder (GAD) has emerged as a significant mental health challenge affecting millions. Recent studies show that anxiety ...

Please provide your email address to receive an email when new articles are posted on . MM-120 demonstrated clinically and statistically significant reductions in anxiety compared with placebo at 12 ...

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

In the “ThemenCheck Medizin” procedure offered by the German Institute for Quality and Efficiency in Health Care (IQWiG), interested members of the public can submit proposals for the assessment of ...

Psychotropic drugs are all the rage now as a potential treatment of brain diseases. Examples are ketamine and psilocybin for depression and PTSD. More recently, a single dose of LSD was found to have ...

Anxiety disorders are a group of disorders that share symptoms like excessive fear and heightened stress (American Psychological Association [APA], 2022). It is important to note that fear and anxiety ...

I recommend an interesting blog on Generalized Anxiety Disorder written by Bruce Jancin in Family Practice News. His basic point is that the changes suggested by the DSM 5 work group are likely to ...

Findings highlight the link between anxiety severity and SI, underscoring the need for routine screening NEW YORK--(BUSINESS WIRE)-- Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the ...

(RTTNews) - Viatris Inc. (VTRS), a healthcare company, Monday said it has submitted Supplemental New Drug Application to Japan's Ministry of Health, Labor and Welfare (MHLW) for Effexor to treat ...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...

NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...